



COLORADO

**Prescription Drug
Affordability Board**

Division of Insurance

Prescription Drug Affordability Board DRAFT Meeting Minutes

Friday, October 3, 2025; 10 am - 1 pm - Virtual Meeting

[Meeting Recording](#)

Meeting Attendance

Board Members

Dr. Gail Mizner
Dr. Justin Vandenberg
Dr. Amy Gutierrez
Dr. Sami Diab
Ms. Cathy Harshbarger

Board Staff

Lila Cummings
Sophie Thomas
Kate Davidson
Bryan Fife
Sagun Sharma
Callie Shelton
Sara Stultz
Rebecca Walker

Agenda

- Call to Order and Roll Call, Board Member and Director Disclosures
- Approval of August 22, 2025 and September 29, 2025 Meeting Minutes
- Director Updates
- Rulemaking Hearing: Prescription Drug Affordability Board Rule 3 CCR 702-9: Part 4.3: Upper Payment Limit for Enbrel
- Break
- Board Business
 - UPL Implementation

Call to Order, Roll Call, Board Member and Director Disclosures

Dr. Gail Mizner called the meeting to order at 10:03 am. Dr. Mizner, Ms. Cathy Harshbarger, Dr. Sami Diab, and Dr. Justin Vandenberg were present. Dr. Amy Gutierrez joined the meeting at 10:08 am.

No Board members disclosed any stakeholder meetings. Board Director, Sophie Thomas, disclosed that Board staff met with Centennial State Prosperity and Bridget Dandaraw-Seritt.

Approval of August 22, 2025 Meeting Minutes

Dr. Vandenberg moved, and Ms. Harshbarger seconded a motion to approve the August 22, 2025 meeting minutes. Dr. Mizner, Ms. Harshbarger, and Dr. Vandenberg voted to approve the minutes. Dr. Diab did not participate in the vote.

[DECISION: August 22, 2025 meeting minutes are approved at 10:05 am.](#)

Approval of September 29, 2025 Meeting Minutes



COLORADO

Prescription Drug
Affordability Board

Division of Insurance

Dr. VandenBerg moved, and Ms. Harshbarger seconded a motion to approve the September 29, 2025 meeting minutes. Dr. Mizner, Ms. HarshBarger, and Dr. VandenBerg voted to approve the minutes. Dr. Diab did not participate in the vote.

DECISION: September 29, 2025 meeting minutes are approved at 10:05 am.

Director Updates

Ms. Thomas noted that the Board and Council staff will be hosting a stakeholder workgroup on October 14, 2025, from 12-3 pm, in collaboration with the Advisory Council during a Prescription Drug Affordability Advisory Council (PDAAC) meeting. The Board and Council staff will engage with stakeholders to identify opportunities for improving practices for collecting patient information during affordability reviews. Fifty people have registered to participate in the workgroup thus far.

Rulemaking Hearing: Prescription Drug Affordability Board Rule 3 CCR 702-9: Part 4.3: Upper Payment Limit for Enbrel

The PDAB was in session for a rulemaking hearing at 10:08 am on PDAB Rule 3 CCR 702-9: Part 4.3: Upper Payment Limit for Enbrel. Dr. Diab did not participate in the rulemaking hearing due to a conflict of interest with Enbrel.

Staff outlined the procedure for the rulemaking hearing. Ms. Thomas presented the description of the rule, followed by staff-presented information for Enbrel on the following:

- Implementation monitoring and enforcement next steps;
- Review of UPL benchmarks and data; and
- Proposed changes to UPL Rule for Enbrel.

The Board began its deliberations on the rule at 10:26 am, including discussion and edits to the rule related to the UPL amount, unit, and effective date.

At 10:50 am, Dr. Gutierrez moved, and Dr. VandenBerg seconded a motion to convene an executive session to receive legal advice regarding the connection to the MFP, the rounding of the upper payment limit number, the clarification on the milligrams, and the impact of incorporating vials and syringe dosage strengths into the definition of UPL, pursuant to section 24-6-402(3)(a)(II), C.R.S. All Board members voted to convene an executive session. Dr. Diab did not attend the session due to his conflict of interest with Enbrel.

DECISION: At 10:50 am, the Board convened an executive session to receive legal advice regarding the connection to the MFP, the rounding of the upper payment limit number, the clarification on the milligrams, and the impact of incorporating vials and syringe dosage strengths into the definition of UPL.

Beginning at 11:24 am, the following individuals offered testimonies to the Board on PDAB Rule 3 CCR 702-9: Part 4.3: Upper Payment Limit for Enbrel:

- Tiffany Westrich Roberston - Ensuring Access through Collaborative Health (EACH) Coalition, and Patient Inclusion Council (PIC)
- Sophia Hennessy - Colorado Consumer Health Initiative (CCHI)
- Derek Flowers - Value of Care Coalition
- Katelin Lucariello - Pharmaceutical Research and Manufacturers of America (PhRMA)



COLORADO

Prescription Drug
Affordability Board

Division of Insurance

- Amy Goodman - Colorado Bioscience Association (CBSA)
- Rae Wall - Voices of Healthcare Action
- Madelaine A. Feldman - Coalition of State Rheumatologist Organizations
- Ingrid Pan - Children's Hospital Colorado

At 12:10 pm, Dr. Gutierrez moved, and Dr. Vandenberg seconded a motion to adopt Prescription Drug Affordability Board Rule 3 CCR 702-9: Part 4.3: Upper Payment Limit for Enbrel as currently presented. Dr. Mizner, Dr. Gutierrez, Ms. Harshbarger, and Dr. Vandenberg voted to adopt the rule as currently presented.

[DECISION: At 12:11 pm, the Board adopted the Prescription Drug Affordability Board Rule 3 CCR 702-9: Part 4.3: Upper Payment Limit for Enbrel as currently presented.](#)

Board Business

UPL Implementation

At 12:13 pm, Board staff presented a high level overview of what staff is looking at for UPL implementation.

Beginning at 12:22 pm, the following individuals offered testimonies to the Board on the adopted Enbrel UPL rule:

- Emily Zadvorny - Colorado Pharmacists' Society
- Primo Castro - Biotechnology Innovation Organization (BIO)
- Carl Ecklund - Caregiver

Note: Although a break was scheduled in the agenda, Dr. Mizner did not call for one during this meeting.

Dr. Mizner adjourned the meeting at 12:37 pm. The next PDAB meeting will be held on Friday, November 14, 2025, at 10:00 am MT.